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ABSTRACT
THE SECOND GENERATION PROTEASOME INHIBITOR CARFILZOMIB
INTERACTS SYNERGISTICALLY WITH HDAC INHIBITORS IN DIFFUSE
LARGE B-CELL LYMPHOMA CELLS THROUGH MULTIPLE MECHANISMS
AND CIRCUMVENTS BORTEZOMIB RESISTANCE
By Dmitry Lembersky, Bachelor of Science
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University.

Virginia Commonwealth University, 2009

Major Director: Dr. Steven Grant, MD
Department of Biochemistry

Mechanisms underlying the interactions between the proteasome inhibitor carfilzomib
and HDAC inhibitors were examined in both germinal center (GC) and activated B-cell
(ABC) subtypes of human diffuse large B-cell lymphoma (DLBCL).

Simultaneous

exposure to minimally toxic concentrations of carfilzomib and HDAC inhibitor vorinostat
resulted in the release of mitochondrial pro-apoptotic proteins SMAC and cytochrome c,
pro-apoptotic caspase activation, and synergistic induction in apoptosis in both ABC and
GC DLBCL subtypes. These events were associated with a marked increase in the stress
kinase JNK, ROS generation, G2-M cell cycle arrest, as well as induction of DNA
damage. Genetic knockdown of JNK resulted in a significant decrease in
carfilzomib/vorinostat induced cell death. Co-administration of the antioxidant MnTBAP
significantly reduced carfilzomib/vorinostat induced cell death, and resulted in a marked
decrease in caspase-3 as well as a striking decrease in JNK phosphorylation. Tumor

vii

growth reduction was also observed in animal models that were treated with a combined
regimen of carfilzomib and vorinostat.

Finally, the combined treatment of

carfilzomib/vorinostat was able to overcome any cross-resistance to carfIlzomib in
bortezomib resistant cells. Collectively, these finding indicate that the combined regimen
of carfilzomib and HDAC inhibitors promote lethality in ABC and GC human DLBCL
cells by a variety of mechanisms both in vitro and in vivo. Further studies are necessary
for clinical development of this drug regimen.
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INTRODUCTION

LYMPHOMA
The groups of cancers under the general term lymphoma are very broad, and
symbolize the disease of the impaired immune system. This includes lymphomas of Bcell origin, T-cell origin, and natural killer cell origin. Lymphomas are broadly classified
into two major groups i.e. Hodgkins (HL) and Non-Hodgkin lymphoma (NHL). The
classifications are based on the differences in characteristics, morphology of the
cancerous cells and prognosis with current therapy.
Diffuse lymphocytic B-cell lymphoma (DLBCL) is the most frequently
encountered lymphoma in adults, accounting for 30-40% of adult neoplasms (1). It is an
aggressive malignancy of mature B lymphocytes, with 25,000 new cases annually,
accounting for roughly 40% of cases of non-Hodgkin's lymphoma. Patients with DLBCL
have highly variable clinical outcomes; although most patients respond initially to
chemotherapy, fewer than half of the patients achieve a durable remission (2). Although
treatment progress, including the development of chemotherapeutic regimens such as RCHOP or advances in bone marrow transplantation have led to an improved prognosis
(3), many patients become resistant to standard therapy and succumb to their disease.
Consequently, novel treatment approaches continue to be sought.
Recently, microarray analyses performed on untreated DLBCL has lead to the
identification of two main sub-types, germinal center (GC-DLBCL), and activated B-cell
(ABC-DLBCL). Both have a distinct gene expression profile, characteristic of either
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normal germinal center b-cells or activated blood memory b-cells (4). The germinal
center-like subgroup is correlated with a significantly better prognosis in comparison
with the activated b-cell like subgroup (4), and the 5-year survival rate of both is 59%
and 30% respectively (5). A third subgroup is comprised of cases that do not express the
genetic profile of wither the ABC or GC subgroups, yet has a poor prognosis similar to
that of the ABC subgroup (4). Different oncogenic mechanisms underlie both the ABC
and GC subgroups, with Bcl2 gene rearrangement occurring almost exclusively with the
GC subgroup (4,6-8), while NF-κB signaling activation occurs in the ABC subgroup (4).
Such findings raise the possibility that novel therapies may ultimately be targeted to
specific DLBCL sub-types (5,6).

The PROTEASOME
The two main routes of protein degradation are proteasomes and lysosomes.
While lysosomes degrade extracellular and transmembrane proteins, proteasomes
primarily degrade intracellular proteins.

This could be due to phosphorylation by

signaling pathways, or they could be recognized as being misfolded. The proteins are
tagged for degradation via an ubiquitin tag (9).
The functionally active 26S proteasomes is an ATP-dependent proteolytic
complex, located in the cytoplasm and nucleus of eukaryotic cells. It is made up of a 20S
core catalytic subunit, capped by both ends by 19S regulatory subunits (9,10). Generally,
the proteasome identifies proteins destined for degradation by their ubiquitin tag,
although ubiquitination is not always necessary for degradation of every protein (9).
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Reproduced from Adams J, 2004
The 20S proteasome subunit is a cylindrical structure composed of 28 protein
subunits, organized into 4 stacked rings. The top and bottom rings are formed by 7
polypeptides, termed α-subunits, and the two inner rings are made up of 7 β-subunits.
The β-subunits contain the enzymatically active sites of the proteasome (9). The β1, β2,
and β5 subunits are characterized as chymotryptic-like, tryptic-like, and post-glutamyl
peptidyl hydrolytic-like (9,11-13).
The 19S regulatory complex contains 20 subunits which bind to both ends of the
20S proteasomes to form the 26S proteasomes (9). ATP hydrolysis is required for both
the formation of the 26S complex and for unfolding proteins for entry into the catalytic
core of the proteasomes (9,12,14). It is therefore possible that the increasing protein
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degradation requirements in rapidly proliferating cancer cells make them more
susceptible to proteasomal inhibition (15).
Targeting the majority of proteins to the proteasome for degradation requires
polyubiquitination, but it can also serve as a signal for trafficking, kinase activation, and
other nonproteolytic activities (9,16).

Conjugation of ubiquitin to a target protein

proceeds in via a three-step mechanism. Initially, ubiquitin is activated in its C-terminal
glycine by the ubiquitin-activating enzyme, E1. Following activation, one of several E2
enzymes (ubiquitin-conjugating enzymes) transfers ubiquitin from E1 to a member of the
ubiquitin-protein ligase family, E3, to which the substrate protein is specifically bound.
This enzyme catalyzes the last step in the conjugation process, covalent attachment of
ubiquitin to the substrate (11). Ubiquitination is not absolutely required for proteasomal
degradation however, as the tumor suppressor RB family proteins can undergo
proteasomal degradation through a ubiquitin-independent pathway.

ER STRESS AND THE UNFOLDED PROTEIN RESPONSE
An excessive accumulation of misfolded proteins within the ER-Golgi network
elicits a cellular response which initially promotes cell survival, but will lead to apoptosis
if the repair mechanisms are overwhelmed (15). The core of this defense system is
known as the unfolded protein response (15,17), which functions to increase expression
of protein chaperones such as Grp78/BiP, in order to limit protein aggregation, to
increase biosynthesis of structural components of the ER, and to inhibit overall protein
synthesis so that the load on the ER-Golgi network is reduced. Upstream control of the
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unfolded protein response is mediated via activation of three ER transmembrane proteins,
the serine/threonine kinase PERK, IRE and the bZIP transcription factor, ATF6
(15,17,18).

The unfolded protein response (UPR). In response to a build-up of misfolded proteins
within the endoplasmic reticulum (ER), the molecular chaperone glucose regulated
protein-78 kD (Grp78, commonly known as BiP) dissociates from the luminal domains of
PKR-like ER kinase (PERK), IRE1, and ATF6, resulting in their activation. PERKmediated phosphorylation of eIF2α coordinates activation of the transcription factor
ATF4 with attenuation of global protein synthesis and activation of autophagy.
Reproduced from McConkey DJ, et al, 2008.

It is unknown exactly how proteins are shuttled to the proteasome for degradation, but
current evidence points to discrete structures known as aggresomes (15,19-21), as well as
the cytosolic chaparone, HSP70 (15,22). The activity of proteasome inhibitors may be
improved by blocking proteasome inhibitor-induced aggresome formation with pan-
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specific chemical HDAC inhibitors such as trichostatin A or vorinostat (SAHA)
(15,23,24). It has been shown that chemical pan HDAC inhibitors are some of the most
potent PI-sensitizing agents, capable of restoring PI sensitivity in cells that are
completely resistant to the agents basally (15,24).

EFFECT OF PROTEASOME FUNCTIONS ON SIGNALLING
It is known that many proteasome substrates are mediators of pathways which are
disregulated in cancers (9), in addition
to it’s conventional role of inhibition of
proteasome synthesis. It is reported that
proteasome inhibitors modulate targets
which govern the growth and survival
of transformed cells like cell cycle, NFκB,

aggresome

formation,

pathways like SAPK/JNK etc.
proteasomes

affects

stress
The

cell-cycle

progression by regulating cyclins, and
can also increase or decrease apoptotic
activity via caspases, Bcl-2, and NF-κB
(9).

Proteasome

inhibition

can

destabilize the regulation of CDC25A,
Reproduced from Adams, 2004

CDC25C, KIP1 and the cyclins, which
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will make the cell more susceptible to apoptosis. Because of the fact that cell cycle
checkpoints in cancer cells are disrupted, the cells may be more heavily dependent on
proteasome-mediated degradation of cell cycle regulators, both positive regulators like
cyclins and negative regulators like p21 and p27, for their survival (15).
The NF-κB family of transcription factors represents proteins bound to the
inhibitor IκB, which while bound, remain inactive in the cytoplasm. In response to
cellular stress, the IκB inhibitor becomes deactivated by the proteasome, which results in
NF-κB translocation into the nucleus and activates several pro-survival pathways (9).
NF-κB has been shown to control cell proliferation by activating genes such as
interleukin 2 (IL-2) and CD40 ligand, all of which are factors that promote proliferation
of lymphoid and myeloid cells (25). In addition, NF-κB has been shown to inhibit
programmed cell death (25-29) by activation of genes known to block apoptosis via
TNFα, as well as others (25,30). The genes that are induced by NF-κB include cellular
inhibitors of apoptosis, caspase-8/FADD, and members of the Bcl-2 family of proteins
(25,30).

Reproduced from Karin M, et al, 2002
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NF-κB has also been shown to attenuate apoptotic responses to genotoxic
anticancer drugs and ionizing radiation (25,29-31), and that inhibition of NF-κB pushes
chemoresistant tumors toward apoptosis (31). In addition to conferring resistance to
cancer therapies, the anti-apoptotic activity of NF-κB can also have an important role in
the emergence of neoplasms, by preventing the death of cells that have undergone
chromosomal rearrangements or other types of DNA damage (25). Diffuse large B-cell
lymphomas that are of the activated B-cell (ABC) phenotype have elevated expression of
NF-κB target genes, which encode cytokines, chemokines and anti-apoptotic proteins
(25), and expression of a non-phosphorylateable IκB mutant (super-repressor) in these
cells inhibits their proliferation (25). In contrast, DLBCLs with a germinal-centre-like
gene-expression profile seem to be resistant to the IκB super-repressor, which indicates
that the canonical NF-κB signaling pathway, which depends on the IKKβ catalytic
subunit and IκB degradation, is constitutively active in the activated B-cell-like DLBCL
cells (25).
Reactive oxygen species (ROS) generation can result in DNA damage as well as
oxidation of fatty acids and proteins. Eukaryotic cells continually produce ROS by
electron transfer reactions, but ROS can be exacerbated by exogenous sources such as
UV light, toxins, or drugs (32).

NF-kB is considered a primary oxidative stress-

responsive transcription factor that enhances the transcription of a variety of genes,
including those for cytokines and growth factors, adhesion molecules, immunoreceptors,
and acute response proteins (32). Most if not all agents that activate NF-κB also trigger
ROS formation
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It is well known that apoptosis requires a cascade of biochemical events,
performed via a family of cysteine proteases called caspases (9). Caspase-9 is the apical
caspase, which directly activates caspases -3 and -7 through proteolytic cleavage (33).
Active caspase-3 processes caspases -2 and -6, and activated caspase-6 activates caspases
-8 and -10 (33). Specifically, it is thought that caspase-8 and caspase-3 are the major
effector caspases, essential for the apoptosis cascade (9,34). Activation of caspase-2 is
caused by cytotoxic stress, and is required for permeabilization of the mitochondria and
the release of SMAC and cytochrome c (35).

Cytochrome c binds to Apaf-1 and

activates caspase-9, which in turn, activates caspase-3 (35). Caspase-4 on the ER is
thought to play a role in ER stress-induced apoptosis (36). Caspase precursors are
constitutively expressed in the cell, and have to be activated via proteolytic cleavage by
specific inducers.

Activation of NFκB can inactivate caspase-8 (9,37), therefore

proteasome inhibition could prevent activation of the anti-apoptotic factor NF-κB,
potentiate caspase activity, and induce apoptosis.

PROTEASOME INHIBITORS
Proteasome inhibitors might be natural or synthetic and five important classes of
proteasome inhibitors exist: peptide aldehydes, peptide vinyl sulphones, peptide
boronates, peptide epoxiketones and β-lactones (9). The natural inhibitor lactacystin and
synthetic peptide aldehydes were the first agents to be identified with the ability to inhibit
proteasomes, yet they suffered from several limatations including poor stability and
bioavailability, and lack of specificity (9,38). Substituting the aldehyde with boronic acid
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would enable the compound to achieve a covalent, reversible interaction with
proteasomes, while achieving improved potency and selectivity. (9,38,39). Bortezomib
was one of the original 13 boronic-acid proteasome inhibitors selected for further study
(9).

Studies have shown that the proteasome inhibitor bortezomib induced ROS

formation, and played a critical role in caspase-9 activation in bortezomib-mediated
apoptosis (40).

BORTEZOMIB
Bortezomib was originally synthesized in 1995 as MG-341 .It was developed by
Millennium Pharmaceuticals. After promising preclinical results, the drug (PS-341) was
tested in a small Phase I clinical trial on patients with multiple myeloma (MM) cancer.
When one of the first volunteers to receive the drug in the clinical trial achieved a
complete response, the drug was given priority at the company, and in 2003, bortezomib
(Velcade) was approved for use in multiple myeloma by the FDA based on the results of
the SUMMIT Phase II trial (38).
Bortezomib is known to bind with 26S proteasome reversibly and cleared very
rapidly from the plasma compartment; achieving 90% clearance within 15 minutes of
intravenous administration (38). There is minimal intersubject and intrasubject variation
in proteasome activity.

The effects of bortezomib are dose related, achieving 80%

proteasome inhibition at a dose of approximately 1.96 mg/m2. Monitoring the extent of
20S proteasome inhibition in PBMCs collected from patients enrolled in Phase I clinical
trials confirmed that levels of inhibition up to 80% did not cause excessive toxicity
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(15,38,41-43). Bioassay testing in rats indicated that most organs received a similar
amount of drug, with no drug present in the testes, eyes, and central nervous system (38).
Proteasome activity is restored 48 to 72 hours after cessation of bortezomib treatment
(38).

CARFILZOMIB (PR171)
Carfilzomib is an epoxyketone that was developed by Proteolix, Inc. (South San
Francisco, CA, USA) (15,44).

Carfilzomib differs from bortezomib in that it is a

irreversible proteasome inhibitor, and it is more selective for the chymotryptic activity
(15,44). More importantly however is the fact that it can be given at a much more
aggressive schedule, ie: doses that cause greater than 80% proteasome inhibition for at
least 5 consecutive days (15,44). Preclinical studies also indicate that PR171 is active
against solid tumors as well as cell lines from patients resistant to bortezomib (Proteolix
pipeline). Recent published result has indicated that carfilzomib is active against
bortezomib resistant cells (45).

HISTONE PROTEINS
Transcription in eukaryotic cells depends on the manner in which the DNA is
packaged (46,47). DNA is tightly compacted into the highly organized protein-DNA
complex chromatin in resting cells to prevent access by transcription factors, thereby
preventing replication. The fundamental subunit of chromatin is called the nucleosome,
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which is composed of an octamer of 4 core histones, for example a H3/H4 tetramer and
two H2A/H2B dimers, surrounded by 146 bp of DNA, Fig. (46). During activation of
transcription, this compact, inaccessible DNA is made available to replication proteins
via nucleosome modification. (46,48).

HISTONE DEACETYLASES
Histone tails are positively charged, due to the amine groups present on their
lysine and arginine amino acids. This allows the positively charged histone tails to
interact with the negatively charged phosphate groups on the DNA backbone, keeping the
DNA tightly compacted. Acetylation partially neutralizes the positive charges of the
histones, allowing for chromatin expansion and gene transcription (49). This process
involves the transfer of an acetyl group from the acetyl coenzyme A metabolic
intermediary to the ε-amino group of lysine residues in histone tails, catalyzed by a group
of enzymes known as histone acetyltransferases (HAT) (49).

Histone deacetylases

remove these acetyl groups, thereby condensing the DNA and promoting transcriptional
repression (49).

HISTONE DEACETYLASE INHIBITORS (HDACi)
Histone deacetylase inhibitors (HDACi) can elicit a range of responses that affect
tumor growth and survival, including inhibition of cell cycle progression, induction of
tumor cell-selective apoptosis, suppression of angiogenesis, and modulation of immune
responses, as well as show promising activity against hematological malignancies in
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clinical trials (50). A major mechanism of apoptosis induction by HDAC inhibitors is
through the induction of oxidative injury, or ROS formation (51). HDAC inhibitors are
considered to be among the most promising agents in drug development for cancer
therapy (52-54), largely because it has been shown that these inhibitors present relatively
low toxicity to normal cells, most likely due to the fact that normal cells are relatively
resistant to HDACi-induced cell death, whereas a broad variety of transformed cells are
sensitive to HDAC-induced cell death (52). There are both natural and synthetic HDAC
inhibitors, and they can be divided into several groups: hydroxamic acid derivatives,
cyclic peptides, short-chain aliphatic acids, and benzamides (52).
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Schematic representation of a nucleosome. Yellow represents the histones. Dark red
depicts the histone tail that can be modi®ed to loosen DNA (purple) winding. The dark
red circle represents a tail without an acetyl (Ac) group. The dark red ` banana shape '
represents a histone tail with an acetyl group, relieving the tight packaging of the DNA.
(B) Transcriptional repression and activation in chromatin. Yellow circles represent core
histone octamers ; in the upper panel, acetylated histone tails (dark red) are depicted
emerging from the octamer (46). Reproduced from de Ruijter, et al, 2003

VORINOSTAT (SAHA)
Vorinostat (SAHA, Zolinza) is a hydroxamic acid derived synthetic compound,
and a pan-inhibitor of Class I and II HDACs (52,55). It is the first HDAC inhibitor
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approved for clinical use in cancer patients for treating cutaneous T-cell lymphoma by
the US Food and Drug Administration. It has been shown to induce cell cycle arrest and
apoptosis and prolong survival in preclinical models of B-cell lymphoma (50,56), and
Phase I trials are showing promising results (56-58).

It is likely necessary to use

vorinostat in combination with other drugs for enhanced therapeutic effects (52).
Already, HDACi have been shown to cooperate with radiation therapy, antitubulin
agents, topoisomerase I and II inhibitors, cisplatin, the kinase inhibitor imanitib,
proteasome inhibitors such as bortezomide, the heat shock protein-90 inhibitor 17-Nallylamino-17-demethoxygeldanamycin, the Her2 receptor inhibitor trastuzumab,
retinoids, inhibitors of DNA methylation, estrogen receptor antagonists, dexamethasone,
and others (52).

RATIONALE FOR COMBINING CARFILZOMIB AND VORINOSTAT
Owing to the poor prognosis of DLBCL patients to bortezomib therapy, newer
and more effective proteasome inhibitor was sought. Development of second generation
proteasome inhibitor i.e. carfilzomib was a step in this direction. A combined drug
regimen to potentiating the activity of carfilzomib will be an attractive option. There are
multiple reasons suggesting combination of carfilzomib and vorinostat may result in a
synergistic interaction. There is evidence that HDAC inhibitors activate the NF-κB
survival pathways (59), whereas proteasome inhibitors block this activation (15). There is
also evidence that proteasome inhibitors like bortezomib induce aggresome formation
(60), which promotes cell survival, whereas HDAC inhibitors block the same (15,23,24).
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In addition, both HDACI and proteasome inhibitors have been shown to induce ROS
generation and oxidative stress (40,51). Therefore, combining the two may result in a
synergistic interaction. Bortezomib and vorinostat have also been shown to interact
synergistically in many cancer cell types, including hematologic malignancies as well as
solid tumors and under clinical trials. In light of all this evidence we propose that
combining carfilzomib and vorinostat will result in a synergistic interaction with respect
to cell death in both GC and ABC DLBCL cell lines.
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MATERIALS AND METHODS

Cells
SUDHL16 cells (GC subtype) was a kind gift from Dr. Alan Epstein, University
of Southern California, LA. SUDHL4, SUDHL6 (both GC), OCI-LY10, OCI-LY3 (both
ABC) were provided by Dr. Lisa Rimsza of University of Arizona, Tucson. Bortezomibresistant SUDHL16-10BR (GC) and SUDHL6-20BR (GC) were generated by exposing
the respective parental cells to progressively increasing concentrations of bortezomib
beginning with 1.0 nM. Once cells developed resistance to bortezomib, they were
cultured in the absence of drug for two weeks prior to experiments. Multiple studies
documented the persistence of drug resistance under these conditions.

SUDHL-10BR

(GC) and Raji-20BR were generated by exposing the respective parental cells to
progressively increasing concentrations of bortezomib beginning with 1.0 nM. Once cells
developed resistance to bortezomib, they were cultured in the absence of drug for two
weeks prior to experiments. Multiple studies documented the persistence of drug
resistance under these conditions.

SUDHL16-sh-JNK cells were generated by

electroporation (Amaxa, GmbH, Germany) using buffer L of a MAP8 shRNA
(SuperArray Bioscience Corporation, Frederick, MD) into SUDHL16 parental cells
according to the manufacturer’s instructions. Stable clones were selected by serial
dilution using G418 as selection marker.
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Cell Culture
Cells were suspended in sterile plastic T-flasks (Corning, NY) and placed in a 5%
CO2, 370C incubator. Cells were counted on a Coulter Counter Cell and Particle Counter,
and split when their counts were at least 9.0 x 105 cells/mL, using RPMI media
containing L-glutamine, pen-strep, non-essential amino acids, all provided by Invitrogen,
and sodium pyruvate and RPMI provided by Mediatech, Manassas, VA. All experiments
were carried out within passage 6-24 to ensure uniformity of drug responses.

Reagents
Carfilzomib (PR171 and PR-047) were provided by Proteolix, San Francisco,
CA. Bortezomib (Velcade) was provided by Millennium Pharmaceuticals, Cambridge,
MA. MnTBAP was provided by Calbiochem, CA. N-Acetyl-L-cysteine was provided by
Sigma-Aldrich, St. Louis, MO. 5-(and-6)-chloromethyl-2’,7’-dichlorodihydrofluorescein
diacetate, acetyl ester (ROS dye) was provided by Molecular Probes, Eugene, OR. 7Aminoactinomycin D was provided by Sigma-Aldrich, St. Louis, MO.

Experimental Format

Logarithmically growing cells were suspended in sterile plastic T-flasks (Corning,
NY), or sterile plastic cell culture plates (Greiner), in media containing 10% FBS
(Atlanta Biologicals, Lawrenceville, GA). Cells were cultured at least 24 hours prior to
treatment with designated drugs. The flasks and plates were then placed in a 5% CO2,
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370C incubator for various intervals. At the end of the incubation period, cells were
transferred to sterile centrifuge tubes, pelleted by centrifugation at 400 x g for 10 min at
room temperature, and prepared for analysis as described below. All cells were tested
regularly for mycoplasma contamination using the MycoAlert Mycoplasma Detection
Kit, provided by Lonza, Inc., Rockland, ME, to insure that cells were free of mycolpasma
prior to experimentation.

All experiments were performed using equivalent cell

concentrations (e.g.,4.0-5.0 x 105 cells/ml) to ensure conformity of drug responses.

Assessment of cell death
Drug effects on cell viability were monitored by flow cytometry using 7AAD as
the staining dye.

Briefly, cells were stained with 25 μM 7AAD solution at room

temperature in regular culture media and analyzed in the FL2 channel using the Becton
Dickinson flow cytometer. Alternatively, cells were washed with 1x PBS and stained
with Annexin V/PI (BD PharMingen, San Diego, CA) for 30min. at room temperature.
Cells were then processed and analyzed using the cytofluorometer. Cells undergoing
apoptosis were also periodically monitored by Annexin V staining to confirm 7AAD
results. Cells were also analyzed for viability using the VIACOUNT reagent in
conjunction with a GUAVA PCA instrument using CytoSoft software as per the
manufacturer’s instructions. Results were verified by Trypan blue staining and
enumeration of Trypan blue excluding cells using a hemocytometer. Results for each of
these methods were found to be in good agreement.
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Collection and processing of primary cells
Primary DLBCL cells obtained with informed consent from the bone marrow of a patient
with DLBCL and extensive marrow infiltration (>70%).

These studies have been

approved by the Investigational Review Board of Virginia Commonwealth University.
Bone marrow samples were collected in sterile syringes containing heparin and processed
by standard techniques to separate mononuclear cells, after which CD34+ cells were
isolated using an immunomagnetic bead separation technique as we have previously
described in detail (61). CD34+ cells were then suspended in RPMI1640 medium
containing 10% FCS and exposed to agents as described above for continuously cultured
cell lines.

Western blot Analysis
Western blot samples were prepared from whole cell pellets. Equal amounts of
protein (30µg) were separated by 4-12% Bis-Tris (Invitrogen) precast gel and probed
with primary antibodies of interest as we have described in detail previously (61). The
sources of primary antibodies were as follows: AIF, cytochrome c, p-JNK, JNK1, pERK, ERK, Mcl-1, Bak, Bid, Bcl-xL, CD20, Bax, Bak, IREα, GRP94, GRP78, XBP, p-cJun, c-Jun, NOXA, Bim and PUMA were from Santa Cruz Biotechnology, Santa Cruz,
CA.; cleaved caspase-8, cleaved caspase-3, p-p38, p38 , p-eIF2a, eIF2a, CF Caspase 9
were from Cell Signaling Technology, Beverly, MA; Caspase7, Caspase2, Mcl-1, XIAP
were from BD Pharmingen (Transduction Laboratories), Lexington, KY; PARP (C-2–
10), Smac was from Upstate Biotechnology, Lake Placid, NY; Caspase-8 was from
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Alexis, San Diego, CA;

Tubulin was from Oncogene, San Diego, CA. Actin was

purchased from sigma, MO. Bcl-2 was from Dako, CA. Caspase 4 was obtained from
Stressgene Bioreagents, Ann, MI. Secondary antibodies were obtained from KPL Protein
Research Products, Gaithersburg, MD, USA.

ROS Generation Analysis
Cells were suspended into 24-well cell culture plates for 24 hours. Two hours
prior to drug treatment, antioxidants MnTBAP or N-Acetyl-L-cysteine were added to the
appropriate wells, and cells were collected, incubated with ROS dye for 20 mins in the
dark at room temperature, and analyzed for ROS generation on the cytofluorometer 30
minutes and 3 hours after drug treatment.

Animal Studies
Animal studies were performed in NIH-III nude mice procured from Charles
River, Wilmington, MA, USA. 10x106 SUDHL4 cells were pelleted by centrifugation,
washed twice with 1X PBS and re-suspended in 75 ul of PBS. Cells were injected
subcutaneously into the right flank. In order to improve the tumor take rate, cells were
extracted from previously formed tumor (designated as SUDHLT cells) and grown for
subsequent injection. Mice were checked two to three times a week for appearance of
tumors. Once the tumors were visible, mice were grouped having at least 3 to 4 tumors
in each group with approximately equal mean tumor volume. Mice were treated with
various concentrations of carfilzomib via tail vein injection twice a week (1st, 2nd, 8th, 9th
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days etc) and vorinostat was administered by IP injection thrice a week (1st, 2nd, 3rd , 8th,
9th, 10th days etc). Tumor volume was measured 2 to 3 times a week with the help of a
caliper using the following formula
Tumor Volume (CC) = Length (mm) X Width (mm)2
2
Mice were sacrificed once tumors were bigger than 2000 cc. Side effects of tumor
growth and treatment was closely monitored by premature death of mice, loss of weight,
and behavioral change such as lack of movement, etc.

Formulation of carfilzomib and vorinostat for in vivo studies
Vorinostat was originally dissolved in DMSO and stored in -800C in small
aliquots. Finally it is diluted in 1:1PEG400 and sterile water to have final composition of
10% DMSO, 45% PEG400, 45% water. Volume of the treatment to each mouse with was
restricted to 100ul or less. Stock carfilzomib was prepared with 10% sulfobutylether
betacyclodextrin in 10mM citrate buffer pH 3.5 (vehicle) at the concentration 2mg/mL
and stored at -800C. Stocks carfilzomib solution was diluted with vehicle every day for
treatment at various doses

NF-κB Activity

Nuclear protein was extracted using Nuclear Extract Kit (Active Motif) and NFκB activity was determined by using an enzyme linked immunosorbent assay (ELISA)
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Kit TransAM NF-κB p65 Transcription Factor Assay Kit (Active Motif), according to
manufacturer’s instructions. Briefly, the activated form of NF-κB that is present in
nuclear extracts was detected by using an anti-p65 specific antibody that recognizes the
NF-κB bound to a consensus DNA oligonucleotide immobilized in a 96-well plate.
Addition of a secondary antibody conjugated to horseradish peroxidase provides sensitive
readout by spectrophotometry.

Cell Cycle Analysis
Cells (4x106 million/sample) were treated with varying drug concentrations,
pelleted in 15 mL tubes, washed with PBS, and fixed in cold methanol and PBS at a ratio
of 1 mL PBS to 3 mL methanol. Cells were stored in -20 C at least for 24 hrs. Cells
were harvested for analysis and washed twice with ice cold PBS. Cells subsequently
stained by 500 ul of 50ug/ml propidium Iodide for 30 minutes and accrued by flow
cytometry.

Individual cells population in each phage was determined with Modfit

software.

Collection of S-100 fraction
Cells were harvested after drug treatment by centrifugation at 600 x g for 10 min
at 4°C.

Cell pellets were washed once with ice-cold PBS and resuspended in five

volumes of buffer A [20 mM HEPES-KOH (pH 7.5), 10 mM KCl, 1.5 mM MgCl2, 1 mM
sodium EDTA, 1 mM sodium EGTA, 1 mM DTT, 0.1 mM phenylmethylsulfonyl fluoride,
and 250 mM sucrose]. After being chilled for 30 min on ice, the cells were disrupted by
15 strokes of a glass homogenizer. The homogenate was centrifuged twice to remove
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unbroken cells and nuclei (750 x g, 10 min, 4°C). S-100 fractions (supernatants) were
then obtained by centrifugation at 100,000 x g, 60 min at 4°C. All steps were performed
on ice or 4°C.

Statistical Analysis
The significance of differences between experimental conditions was determined
using the two-tailed Student t test. Characterization of synergistic and antagonistic
interactions was performed using Median Dose Effect analysis in conjunction with a
commercially available software program (CalcuSyn, Biosoft, Ferguson, MO).
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RESULTS
Proteasome inhibitors and HDAC inhibitors interact synergistically in a variety of
DLBCL cell types
Interactions between the proteasome inhibitor carfilzomib and HDAC inhibitors
vorinostat and SBHA were assessed in SUDHL16 and SUDHL4 cells, which are both GC
subtype, as well as OCI-Ly10 cells, which are the ABC subtype. Individual exposures to
low concentrations of carfilzomib and vorinostat for 16-24 hours induced limited lethality
(e.g. 15-20% cell death). Combined exposure for 16-24 hours however, resulted in a
marked increase in cell death, e.g. ~70-75% (Figure 1A), with CI values less than 1.0 by
Median Dose effect analysis denoting synergism (Figure 1B).
To determine whether these findings are limited to carfilzomib and vorinostat,
similar experiments were performed with SBHA, a commercially available HDAC
inhibitor. Our results indicate that interactions between proteasome inhibitors and HDAC
inhibitors are not restricted to carfilzomib and vorinostat (Figure 1A). Experiments
performed with another HDAC inhibitor MS-275 resulted in similar synergistic
interaction (data not shown). Sequential treatment of SUDHL16 cells with carfilzomib
and vorinostat resulted in response similar to that of simultaneous treatment regardless of
which drug was treated first (Figure 1C).
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Fig. 1A: Proteasome inhibitors and HDAC
inhibitors interact synergistically in a variety of
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Fig. 1B: Median dose effect analysis for
SUDHL16 cells
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Fig. 1C: Sequential treatment with carfilzomib and
vorinostat on SUDHL16 cells.
Figure 1 Proteasome inhibitors and HDAC inhibitors interact synergistically in a variety of DLBCL
cells
(A). SUDHL16, SUDHL4, and OCI Ly10 cells we treated with minimally toxic concentrations of
carfilzomib ( 2-5nM) ± vorinostat (0.75-2.0uM), or SBHA (30-60uM) for 24-48 hrs, after which cell
death was monitored by 7AAD/DiOC6 staining. (B). Fractional Effect values were determined by
comparing results to those of untreated controls, and Median Dose Effect analysis was employed to
characterize the nature of the interaction. Combination Index (C.I.) values less than 1.0 denote a
synergistic interaction. (C). Sequential treatments were carried out in SUDHL16 cells, starting with
pretreatment of either carfilzomib or vorinostat for 8hrs followed by the second drug for another 16
hours after which cell death was monitored by 7AAD/DiOC6 staining.
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Carfilzomib and vorinostat interact synergistically in DLBCL primary patient
samples with minimal toxicity to normal cells
Interactions between proteasome inhibitors and HDAC inhibitors were assessed in
primary DLBCL patient samples collected from patients to verify whether our findings of
synergistic interaction of carfilzomib and vorinostat can be re-capitulated in primary
cells. Individual exposure (10 hrs for samples presented in Figure 2A, 2B and 24 hrs for
the sample presented in Figure 2C) to low concentrations of carfilzomib and vorinostat in
ABC DLBCL cells (Figure 2A) induced limited lethality over control, while the
combination produced a marked increase in lethality. Similar results were obtained in
DLBCL cells from a patient who was not pretreated with any agents (Figure 2B), as well
as in GC DLBCL cells from a relapsed patient albeit with higher doses, (Figure 2C). To
determine whether this drug combination is toxic to normal cells, CD34+ cells separated
from bone marrow of a healthy donor were treated with 10 nM and 100 nM of
carfilzomib and 1.5 µM of vorinostat. Both 10 nM and 100 nM concentrations or
carfilzomib, as well as 1.5 µM vorinostat were minimally toxic to normal cells. Minimal
toxicity was observed in cells treated with 10 nM carfilzomib and 1.5 µM vorinostat, and
moderate toxicity was observed in cells treated with 100 nM carfilzomib and 1.5 µM
vorinostat. However, no synergistic interaction was observed between these agents in
these cells (Figure 2D).
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10 nM and 100 nM carfilzomib and 1.5 µM
vorinostat.

Fig. 2C. 07-109-V015: Patient was previously
treated with CD20 antibody and relapsed. The
current phenotype is CD5+19+20-. The
original diagnosis was consistent with germinal
center.

Figure 2: Carfilzomib and vorinostat also interact synergistically in DLBCL primary patient samples
(A-C) Primary cells obtained from patients as described in Methods and exposed to carfilzomib (2 100nM) and Vorinostat (0.5 -1.0M) for 10 - 24 hrs. The percentage of apoptotic cells was determined
by Annexin V/PI staining and flow cytometry, and the percentage of viable cells in each sample was
normalized to controls. (D) Normal CD34+ cells were exposed to similar treatments.
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Combined exposure of DLBCL cells to carfilzomib and vorinostat induces
mitochondrial injury, caspase activation in association with marked JNK activation
and induction of DNA damage
Treatment of SUDHL16 (a GC type DLBCL cells) for 14 hours with minimally
toxic concentrations of carfilzomib and vorinostat resulted in a pronounced increase in
activation of caspases-3, -8, -9 as well as release of mitochondrial pro-apoptotic proteins
cytochrome c and SMAC (Figure 3A). Similar results were obtained with other DLBCL
lines (e.g. SUDHL4; data not shown).
Effects of the combination were then examined in relation to MAPK signaling in
SUDHL16 cells. While individual treatment of carfilzomib and vorinostat had little
effect, combined treatment resulted in a dramatic increase in phosphorylation of the
stress-related JNK kinase and that of its substrate c-Jun, as well as it’s upstream target
SEK1 (Fig 3B). In addition, carfilzomib alone induced p38 MAPK phosphorylation, but
this was marginally enhanced by vorinostat (Figure 3B).
In view of evidence linking proteasome inhibitor lethality and induction of ER
stress (54), effects of the combination were examined with respect to several ER stress
markers. Whereas individual exposure exerted minimal effects, combined treatment
resulted in modest but discernible increase in caspase-2 and a significant increase in
caspase-4 cleavage/activation(Figure 3A). However we have also investigated the effect
of carfilzomib and vorinostat on other ER related targets such as eIF2 phosphorylation,
ATF4, PERK, etc which are considered to be the hallmark of ER stress induction, but we
have not observed any major changes (data not shown).
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There is a marked increase in the DNA damage marker γH2AX (Figure 3C).
Also, we observe a notable decrease in the phosphorylation of AKT, as well as an
increase in p21 and SOD2. Interestingly, this combination induced a marked increase in
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Figure 3: Effects of carfilzomib and vorinostat on expression of relevant target proteins
Cells were treated with minimally toxic concentrations of carfilzomib (2-5 nM) ± vorinostat (0.75-2.0
uM) for 24-48 hrs. After treatment cells were lysed, protein denatured, and subjected to Western blot
analysis with the indicated primary antibodies. Blots were then stripped and reprobed with anti-actin
or anti-tubulin to ensure equal loading and transfer of protein (20 μg in each lane). (A) markers of
apoptosis, (B) MAPK pro-apoptotic pathway, (C) DNA damage markers, (D) other relevant targets.
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Combined treatment of carfilzomib and vorinostat blocks the vorinostat induced
activation of NF-κB.
It was previously reported that proteasome inhibitor bortezomib blocks the HDAC
inhibitors induced Nf-κB activation which may be responsible, at least partly for their
synergistic interaction. To whether similar phenomenon also involved in the interaction
of carfilzomib and vorinostat, we treated SUDHL4 cells with minimally toxic
concentrations of carfilzomib and vorinostat produced a significant decrease in NF-κB
activity. Vorinostat alone resulted in a pronounced increase of NF-κB activity, which
was significantly reduced in combination (Figure 4A).

As expected, increasing the

concentration of carfilzomib decreased NF-κB activity (Figure 4B).
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Fig. 4A. Co-administration of carfilzomib and
vorinostat decreases NF-κB activity in SUDHL4
cells

Fig. 4B. Increasing carfilzomib concentration
decreases NF-κB activity in SUDHL4 cells.

Figure 4: Effects of carfilzomib and vorinostat on NF-κB activity in SUDHL4 cells
Nuclear protein was extracted using Nuclear Extract Kit (Active Motif) and NF-κB activity was
determined by using an enzyme linked immunosorbent assay (ELISA) Kit TransAM NF-κB p65
Transcription Factor Assay Kit (Active Motif), as described in Methods. (A) Vorinostat alone
increases NF-κB activity, which is subsequently blocked by co-administration of carfilzomib. (B)
Increasing concentrations of carfilzomib alone decreases NF-κB activity.
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Enhanced JNK activation plays a significant
carfilzomib/vorinostat lethality in DLBCL cells.

functional

role

in

To gain insights into the functional role of JNK activation in lethality of
carfilzomib and vorinostat a genetic approach was employed. ShRNA knockdown of
JNK1 (Figure 5A) in SUDHL 16 cells significantly diminished carfilzomib/vorinostatmediated apoptosis (Fig 5B). It is consistent with other published results and suggests
that JNK activation plays a functional role in the activity of this drug regimen.
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Fig. 5B. Downregulation of JNK1 by shJNK significantly
decreases apoptosis in SUDHL16 cells.
Figure 5: Enhanced JNK activation plays a significant functional role in carfilzomib/vorinostat
lethality in DLBCL cells
SUDHL16 cells were stably transfected with JNK shRNA or vectors encoding a scrambled sequence
were exposed to 3.0 nM carfilzomib and 0.75 µM vorinostat. After 24 hr of drug exposure, apoptotic
cells were monitored by 7AAD and DiOC6 staining and flow cytometry. (A) Effect of JNK1
knockdown on carfilzomib/vorinostat lethality. (B) Western blot showing extent of JNK1 suppression.
For (B) ** sigmificantly lower than values for empty vector controls; p < 0.05
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Carfilzomib and vorinostat induced synergistic lethality involves ROS generation in
SUDHL16 cells
Since proteasome inhibitor and HDAC inhibitors are known to induce oxidative
stress (62,63), we further studied whether combined treatment of carfilzomib and
vorinostat can further induce ROS generation when treated with sub-lethal concentration.
Exposure of SUDHL16 cells (3 hr) to 3.0 nM carfilzomib and 0.75 µM vorinostat
resulted in a marked increase in ROS generation, which was significantly reduced by coadministration of the antioxidant MnTBAP (Figure 6A).

Co-administration of the

antioxidant MnTBAP resulted in a significant decrease in cell death (Figure 6B). Coadministration with MnTBAP also significantly reduced caspase-3 activation as well as
JNK phosphorylation (Figure 6C), both indicative of reduced cell death.
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Figure 6: Carfilzomib/vorinostat lethality involves ROS generation in DLBCL cells
(A) SUDHL16 cells (preteated with or without 5 mM MnTBAP for 3 hrs) were exposed to 3.0 nM
carfilzomib ± 0.75 µM vorinostat for 4 hrs. At the end of the drug exposure, ROS generation was
monitored via flow cytometry as described in Methods. (B) SUDHL16 cells (preteated with or without
75 mM MnTBAP for 3 hrs) were exposed to 3.0 nM carfilzomib ± 0.75 µM vorinostat for 24 hrs. At
the end of the drug exposure, cell death was monitored by 7AAD/DiOC6 staining as described in
Methods. (C) SUDHL16 cells (preteated with or without 75 mM MnTBAP for 3 hrs) were exposed to
3.0 nM carfilzomib ± 0.75 µM vorinostat for 24 hrs. At the end of the drug exposure, cells were
harvested, lysed, protein denatured, and subjected to Western blot analysis with the indicated primary
antibodies.
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Co-administration of carfilzomib and vorinostat causes cell cycle arrest in the G2-M
phase in both GC and ABC DLBCL subtypes

To gain insight into whether or not this drug combination causes cell cycle arrest, we
analyzed the cell cycle in both GC and ABC subtypes. Single treatments with minimally
toxic concentrations of carfilzomib (7.5 nM) and vorinostat (1.5 µM) in OCI-Ly10 ABC
type DLBCL cells resulted in minimal cell cycle arrest in the G2-M phase, while
combinational treatments resulted in a marked increase in G2-M arrest (Figure 7A).
Parallel experiment was carried out in SUDHL4 cells, which are of the GC subtype, and
while minimally toxic concentrations of carfilzomib (5.0 nM) and vorinostat (1.5 µM)
resulted in minimal G2-M arrest, combination therapy resulted in a very large increase in
G2-M arrested cells (Figure 7B).
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Figure 7: Co-administration of carfilzomib and vorinostat results in G2-M cell cycle arrest in both ABC and GC DLBCL subtypes.
OCI Ly10 and SUDHL4 cells were treated with carfilzomib and vorinostat as indicated. After treatment, cells were collected,
fixed in ice cold methanol at a ratio of 1 mL PBS to 3 mL methanol, and analyzed by flow cytometry as described in Methods. (A)
OCI Ly10. (B) SUDHL4.
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There is minimal cross-resistance to carfilzomib in bortezomib resistant DLBCL
lymphoma cells, and is overcome by a synergistic combined treatment of carfilzomib
and vorinostat.
Since patients treated with bortezomib often relapse and become resistant to their
treatment, we examined whether or not there is cross resistance to carfilzomib in
bortezomib resistant DLBCL cells. To determine whether similar interactions might
occur in cells resistant to bortezomib, SUDHL16 and Raji cells that had been adapted to
grow in the presence of bortezomib were employed. These cells (e.g. SUDHL16-10BR,
Raji-20BR) were maintained in the presence of 10nM and 20nM of bortezomib
respectively without any impact on cell growth or viability. These cells express
equivalent CD20 expression, compared to their parental counterparts, confirming their Bcell origin (64). To rule out the possibility that bortezomib resistance might reflect
development of the multi-drug resistance (MDR) phenotype, Pgp expression was
monitored by flow cytometry. No increase in Pgp expression was observed in either
resistant cell line, nor did cross-resistance to VP-16, a Pgp substrate, occur (data not
shown).
Both Raji-20BR and SUDHL16-10BR cells exhibited minimal cross resistance to
carfilzomib (Figure 8A-B). This cross-resistance is easily overcome via combinational
treatments using minimally toxic concentrations of carfilzomib (5-15 nM) as well as
vorinostat (1.5-2.0 μM) and SBHA (40-60 μM) in both SUDHL16-10BR and Raji-20BR
cell lines, as combined exposure for 16-24 hours resulted in a marked increase in cell
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death, e.g. ~65-75% (Figure 8C). CI values less than 1.0 by Median Dose effect analysis
denoting synergism (Figure 8D).
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Figure 8: Minimal cross-resistance to carfilzomib was observed in bortezomib resistant DLBCL
lymphoma cells, and is overcome by co-administration of carfilzomib and vorinostat.
(A-B) Raji-20BR and SUDHL16-10BR were treated with increasing concentrations of carfilzomib as
indicated, and cell death was monitored by 7AAD/DiOC6 staining. (C) SUDHL16-10BR and Raji20BR cells were treated with minimally toxic concentrations of carfilzomib (5-15nM) ± vorinostat
(1.5-2.0μM), or SBHA (40-60μM) for 24-48 hrs, after which cell death was monitored by
7AAD/DiOC6 staining. (D) Fractional Effect values were determined by comparing results to those of
untreated controls, and Median Dose Effect analysis was employed to characterize the nature of the
interaction. Combination Index (C.I.) values less than 1.0 denote a synergistic interaction.
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Co-administration of carfilzomib and vorinostat induce in vivo tumor growth
reduction in SUDHL4T cells

We have further investigated the antitumor activity of carfilzomib and vorinostat
in BNX mice (NIH-III) bearing established human tumor xenografts derived from
SUDHL4T cells as described in methods. First we have evaluated the antitumor effect of
carfilzomib and vorinostat alone against this SUDHL4T tumor cells. Carfilzomib was
administered in doses of 0.5 mg/Kg, 2.0 mg/Kg, and 3.0 mg/Kg and we have observed
dose dependent reduction of tumor growth starting with 2.0 mg/Kg (Figure (9A & 9B).
We have also observed that treatment with vorinostat (75 mg/Kg) also induced significant
tumor growth reduction (Figure 9C). Based on the results of single drug response of
carfilzomib and vorinostat, we have performed two separate set of experiments with the
following dosing
Experiment -1

carfilzomib – 1.5 mg/kg & vorinostat – 40 mg/kg

Experiment -2

carfilzomib – 3.0 mg/kg & vorinostat – 60 mg/kg

Each group of the experiment has four groups of mice, with each group having 3-4 mice
treated. One group of mice was treated with vehicle, where as two groups were treated
with either carfilzomib or vorinostat alone and remaining groups was treated with
combined dose of carfilzomib and vorinostat. Based on the results of four weeks of
dosing, we have observed that co-treatment of carfilzomib and vorinostat have induced
significantly more growth reduction of tumors in comparison to the single drug treatment
(Figure 9D & 9E). However we have not observed any tumor regression in any of the
mice.

39

Fig. 9A. Photographs taken of mice treated with increasing doses of carfilzomib
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Fig. 9B. Tumor volumes in mice treated with
increasing concentrations of carfilzomib.

Fig. 9C. Tumor volumes in mice treated with
75 mg/Kg of vorinostat
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Fig. 9D. Tumor volumes in mice treated with
1.5 mg/Kg carfilzomib and 40 mg/Kg
vorinostat
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vorinostat

Figure 9: Carfilzomib and vorinostat cause tumor growth reduction in SUDHL4T cells
NIH-III nude mice were treated with carfilzomib ± vorinostat as previously described in Methods, at
the indicated concentrations. (A) Photographs of single treatments with carfilzomib. (B-C) Tumor
volumes after single treatments with carfilzomib and vorinostat at the indicated concentrations. (D-E)
Tumor volumes after co-administration of carfilzomib and vorinostat as described in Methods, at the
indicated concentrations. For (A) & (B) * = significantly grater than values for carfilzomib and
vorinostat treatment alone; p < 0.05
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DISCUSSION
Since recent reports of clinical trials of Bortezomib in diffuse large b-cell
lymphoma patients have demonstrated poor clinical response (3,65), development of
alternative therapeutic options based on new generation of proteasome inhibitors may be
an attractive choice. Second generation of proteasome inhibitors, i.e. carfilzomib which
has been reported to have improved efficacy to bortezomib, can logically be used to
develop a drug regimen to treat DLBCL patients.

The present evidence extends previous findings that HDAC inhibitors activate the
NF-κB survival pathways (59), whereas proteasome inhibitors block this activation (15).
Bortezomib and vorinostat have also been shown to interact synergistically in many
cancer cell types, including hematologic malignancies as well as solid tumors, and this
study extends these finding to the second generation proteasome inhibitor carfilzomib
and DLBCL cells. There is clear synergy in combinations of carfilzomib and vorinostat
in diffuse large B-cell lymphoma cell lines and patient samples. Several mechanisms
appear to be playing a role in this combined lethality, including mitochondrial outer
membrane permeabilization, caspase activation, ROS generation, and cell cycle arrest.

Recently, microarray analyses performed on untreated DLBCL has lead to the
identification of two main sub-types, germinal center (GC-DLBCL), and activated B-cell
(ABC-DLBCL). Both have a distinct gene expression profile, characteristic of either
normal germinal center b-cells or activated blood memory B-cells (4). The germinal
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center-like subgroup is correlated with a significantly better prognosis in comparison
with the activated B-cell like subgroup (4), and the 5-year survival rate of both is 59%
and 30% respectively (5). A third subgroup is comprised of cases that do not express the
genetic profile of either the ABC or GC subgroups (4) was not the subject of this study.
Synergistic interactions with carfilzomib and vorinostat on cell death were observed in
both GC and ABC DLBCL cells, and similar results were obtained with other HDAC
inhibitors such as SBHA and MS-275. Therefore these results are applicable to other
classes of HDAC inhibitors, and are not restricted to vorinostat alone. Combinationinduced cell death did not appear to depend on whether the treatment was sequential or
consecutive, as the results for both studies were very similar.

Similar synergistic

interactions were also observed in both the ABC and GC subgroups of patient samples,
including samples from relapsed patients.
For any cancer treatment regimen to be viable and effective, it must not be overly
toxic to normal cells. It is important to note that no synergistic interaction with the two
compounds was observed in CD34+ normals, indicating that this treatment regimen
presents minimal toxicity to untransformed cells.

The stress-related MAPK JNK is known to exert a pro-apoptotic role in cellular
responses to diverse noxious stimuli (66).

JNK activation has been implicated in

proteasome inhibitor lethality in both hematopoietic (40,61) and non-hematopoietic
malignant cells (67). Our results show significant phosphorylation of JNK, as well as
phosphorylation of its upstream target SEK1 and its downstream target c-Jun.
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To

confirm the functional role of JNK in the combinational regimen of carfilzomib and
vorinostat, a genetic shRNA knockdown of JNK was employed. This approach resulted
in a significant reduction in cell death, as well as caspase-3 activation and JNK
phosphorylation (data not shown), indicating that the JNK MAPK pathway is playing a
role in carfilzomib and vorinostat combination induced apoptosis.
To determine the effect of the combination regimen on various relevant target
proteins, we performed western analyses on whole cell lysates.

Our data shows

significant pro-apoptotic caspase activation, marked increase in the oxidative stress
marker SOD2, marked decrease in AKT, and marked increase of the DNA damage
marker γH2AX.

Interestingly, there was a large increase in ERK (p44/42)

phosphorylation, indicating that the pro-survival pathway is being activated even in
combination.
In light of evidence that proteasome inhibitors and HDAC inhibitors both induce
ROS generation and oxidative stress (40,51), we looked to see whether this event plays a
role in apoptosis as a result of combinational treatment with the two compounds. Single
treatments of SUDHL16 cells with either carfilzomib or vorinostat resulted in a moderate
increase in ROS generation, however combining the two compounds resulted in a very
profound ROS increase as well as cell death.

Co-administration of the MnTBAP

antioxidant with carfilzomib and vorinostat significantly blocked ROS generation and
resulted in a significant reduction of cell death.

In addition, co-administration of

MnTBAP together with carfilzomib and vorinostat resulted in a marked decrease in the
activation of the apoptotic effecter caspase-3, a phenomenon known to play an important
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role in mediating the cellular response to oxidative injury (51,68). A profound reduction
in the phosphorylation of JNK, part of the stress-related pro-apoptotic pathway (66) was
also observed in the combined regimen of carfilzomib and vorinostat. Finally, NF-κB is
known to play a major protective role in cells undergoing oxidative damage (32), thus the
carfilzomib/vorinostat regimen may trigger cell death through multiple mechanisms,
including ROS generation as well as a reduction in NF-κB activation. These results
provide support for the notion that disruption of the cellular redox state may represent an
important mechanism underlying DLBCL cell death when exposed to these compounds,
both alone and in combination.
Combined exposure of both GC and ABC DLBCL cells was associated with cell
cycle perturbation. Minimally toxic concentrations of vorinostat alone had little effect on
cell cycle arrest, while carfilzomib alone resulted in a slight increase cells population in
G2-M phase. Combined treatments however resulted in profound increases of G2-M
arrested cells. This evidence suggests that cell cycle arrest from a regimen combining
carfilzomib and vorinostat may play a role carfilzomib and vorinostat mediated cell
death. This is very much in accord with our finding that combined treatment of
carfilzomib and vorinostat induces DNA damage as evident from the up regulation of
γH2AX
The NF-κB pathway is known to play a crucial role in DLBCL cell survival (9),
and the capacity of carfilzomib to inhibit the NF-κB pathway by blocking protesomal IκB
degradation likely plays a key role in the activity of this agent against DLBCL cells. In
accordance with this evidence, our findings show that increasing concentrations of
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carfilzomib block activation of NF-κB.

In accordance with evidence that HDAC

inhibitors induce NF-κB activation (59), our studies show a profound increase in NF-κB
activation in vorinostat-treated cells.

Combined exposure of SUDHL4 cells to

carfilzomib and vorinostat was associated in a very substantial decline in NF-κB activaty.
These findings demonstrate a potential pathway for the synergy of carfilzomib and
vorinostat.
Acquired resistance to treatment is always a concern in patients currently
undergoing therapy, especially if the patient has relapsed. To address this concern, we
examined whether or not there is cross resistance to carfilzomib in bortezomib resistant
DLBCL cells. We generated SUDHL16 cells resistant to 10 nM bortezomib (SUDHL1610BR), and Raji cells resistant to 20 nM bortezomib (Raji-20BR), with both lines having
an 4-5 fold increase of LC50 than the parental cells. Both SUDHL16-10BR and Raji20BR cells exhibited partial cross resistance to carfilzomib.

Upon treatment of the

resistant lines with a combined regimen of carfilzomib and vorinostat, we saw a profound
synergistic response in both resistant cell lines, indicating that this combination regiment
can be an attractive option in patients that developed resistant to other proteasome
inhibitors.
In vivo studies are crucial to confirm the efficacy of this drug combination
regimen. Our early in vivo studies were performed with single drug dosing by injecting
NIH-III beige nude mice subcutaneously with SUDHL4 cells passaged from extracted
tumors that developed in athymic nude mice, in order to determine the dose-response.
These passaged cells were given the SUDHL4T designation. Our results indicated that
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increasing concentrations of carfilzomib had a marked effect on the growth rate of
SUDHL4T tumors, and a 75 mg/kg dose of vorinostat had a profound effect on tumor
growth. Two experiments with combining carfilzomib and vorinostat were performed:
the first used 1.5 mg/kg of carfilzomib and 40 mg/kg of vorinostat and the second used
3.0 mg/kg of carfilzomib and 60 mg/kg of vorinostat. Both combinations resulted in a
decrease in tumor volume when compared to single drug treatments and the control, with
the higher dose resulting in a slightly better effect. However, we have not seen any tumor
regression in any of the experiments. These findings may suggest that animals should be
treated for longer period of time, treatments should be performed more frequently, or the
concentrations of drugs should be optimized further. Since we also observed a large
increase in ERK phosphorylation induced by the combination of carfilzomib and
vorinostat in vitro, it may be worthwhile to combine carfilzomib and vorinostat with a
MEK inhibitor such as PD184352. It will also be interesting to see if we can improve the
in-vivo efficiency by sequentially scheduling the drug treatment rather than administering
the agents simultaneously.

In conclusion, our evidence supports the notion that combining the secondgeneration proteasome inhibitor carfilzomib with the HDAC inhibitor vorinostat presents
a viable treatment option for both germinal center and activated B-cell type DLBCL.
Cell death is mediated by various mechanisms, including ROS generation, cell cycle
arrest, JNK activation, induction of DNA damage, and NF-κB inhibition. This regimen is
effective in both cell lines as well as patient samples, and is able to overcome any cross
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resistance to the first-generation proteasome inhibitor bortezomib.

Finally, this

combination shows promising results in vivo and requires further investigation for
clinical development.
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